-
FDA Approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma
AmericanPharmaceuticalReview
December 03, 2021
The FDA has approved daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior ...
-
NICE recommends Kyprolis triple combination treatment for multiple myeloma
pharmatimes
March 22, 2021
The National Institute for Health and Care Excellence (NICE) has recommended a triple combination therapy comprised of Amgen’s Kyprolis, lenalidomide and dexamethasone for the treatment of previously-treated multiple myeloma patients.
-
FDA Approves New Kyprolis, Darzalex Combination Regimen
americanpharmaceuticalreview
August 25, 2020
Amgen announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the Kyprolis? (carfilzomib) U.S. prescribing information to include its use in combination with Darzalex? (daratumumab) plus dexamethasone (DKd) in two dosing ...
-
KYPROLIS, DARZALEX Combo Approved for Multiple Myeloma
contractpharma
August 24, 2020
The study's primary endpoint resulted in a 37% reduction in the risk of disease progression or death.
-
Amgen Submits Supplemental New Drug Application for Kyprolis
americanpharmaceuticalreview
August 28, 2018
Amgen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for Kyprolis (carfilzomib) to include a once-weekly dosing option in combination with dexamet
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
